Triumvira Immunologics’ Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors

TAC01-CLDN18.2 was well tolerated, with no dose-limiting toxicities and a favorable safety profile in the first two cohorts of the ongoing trial A pancreatic cancer patient treated with the lowest dose has demonstrated clinical benefit for nearly eight months and achieved a confirmed…